Publicaciones en las que colabora con Victor Mangas Sanjuan (13)

2023

  1. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

2021

  1. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

  2. The role of mathematical models in immuno-oncology: Challenges and future perspectives

    Pharmaceutics, Vol. 13, Núm. 7

2018

  1. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  2. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

  3. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2016

  1. Population pharmacokinetic model of lithium and drug compliance assessment

    European Neuropsychopharmacology, Vol. 26, Núm. 12, pp. 1868-1876

  2. Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects

    British Journal of Clinical Pharmacology, pp. 92-107

2015

  1. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

    European Journal of Pharmaceutical Sciences, Vol. 74, pp. 86-94

  2. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules

    Journal of Pharmacology and Experimental Therapeutics, Vol. 354, Núm. 1, pp. 55-64

  3. Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients

    European Journal of Pharmaceutical Sciences, Vol. 73, pp. 57-63